^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19-CAR_Lenti T cells

    i
    Other names: CD19-CAR_Lenti T cells
    Associations

    News

    Trials
    Company:
    Bambino Gesu Hospital
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2d
    CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML (clinicaltrials.gov)
    P1/2, N=32, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • CD19-CAR_Lenti T cells